TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets

May 16, 2024 14:58:21

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs more effectively across the blood-brain barrier. “DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its unique ability to improve drug bioavailability, a critical marker and determinant of overall drug effectiveness,” a recent article reads. “With this technology, Lexaria looks to tap into various growing markets, among them the cardiovascular drugs and diabetes markets, both projected to be valued at $115.8 billion and $134.1 billion by 2028 and 2030, respectively. It also hopes to make drugs more effective, possibly reducing the cost of treatment and improving the patients’ overall quality of life. The company is also aggressively pushing for its patent applications and approvals globally, a show of commitment to creating shareholder value. In addition to its focus on GLP-1 clinical studies for the 2024 calendar year, Lexaria is confident that it will carve out a decent market share for itself, ultimately making 2024 its biggest year yet.”

To view the full article, visit https://ibn.fm/s73Q9

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is powered by IBN